Miltefosine Susceptibility and Resistance in Leishmania: From the Laboratory to the Field
Adriano C. Coelho*
Departamento de Parasitologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, 05508-900, SP, Brazil
- *Corresponding Author:
- Adriano C. Coelho
Departamento de Parasitologia
Instituto de Ciências Biomédicas
Universidade de São Paulo
São Paulo, 05508- 900
E-mail: [email protected]
Received Date: January 20, 2016; Accepted Date: February 04, 2016; Published Date: February 11, 2016
Citation: Coelho AC (2016) Miltefosine Susceptibility and Resistance in Leishmania: From the Laboratory to the Field. J Trop Dis 4:203. doi:10.4172/2329-891X.1000203
Copyright: © 2016 Coelho AC. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Miltefosine is the first effective oral drug used in the chemotherapy of leishmaniasis. The drug is more effective than pentavalent antimonials that are still considered as the drug of choice for treatment of leishmaniasis in several endemic regions. Efficacy rates of miltefosine against visceral leishmaniasis are up to 95%, while against cutaneous leishmaniasis the rates vary between 53% and 91% depending on the species of the parasite and the endemic region. Recent reports have described an increased number of relapses in miltefosine-treated patients. This review describes the main findings associated with miltefosine susceptibility and resistance in Leishmania: two important factors involved in efficacy and failure in leishmaniasis treatment using this drug.